ADMA Biologics Reports Record 2025 Financials, Driven by ASCENIV Growth and Strategic Initiatives

summarizeSummary

ADMA Biologics reported record 2025 revenues of $510.173 million (+20%) and Adjusted EBITDA of $231.030 million (+40%), driven by strong ASCENIV sales and strategic operational improvements. The company also detailed a $500 million share repurchase program and pipeline advancements.

check_boxKey Events

• Record 2025 Financial Performance

  Reported record total revenues of $510.173 million for 2025, a 20% increase from $426.454 million in 2024. Adjusted EBITDA grew 40% to $231.030 million, reflecting strong operational performance.

• ASCENIV Sales Drive Revenue Growth

  ASCENIV sales increased by 51% to $362.531 million in 2025, demonstrating continued physician, payer, and patient acceptance.

• Strategic Plasma Center Divestiture

  Entered an agreement in December 2025 to divest three plasma collection centers for $12.0 million, with two sales completed in February 2026. This move aims for a more capital-efficient supply model and includes long-term plasma supply agreements with the purchaser, with an anticipated gain of $8.0 million.

• Share Repurchase Program Initiated

  The Board authorized a $500 million share repurchase program in May 2025, with $32.090 million in shares repurchased during 2025, signaling confidence in the company's valuation.

auto_awesomeAnalysis

ADMA Biologics filed its annual 10-K, confirming strong financial performance for fiscal year 2025. The company achieved record revenues of $510.173 million, a 20% increase year-over-year, primarily driven by a 51% surge in ASCENIV sales. Adjusted EBITDA also saw substantial growth, rising 40% to $231.030 million. While GAAP net income decreased compared to 2024, this was largely due to a non-recurring deferred tax benefit recognized in the prior year, making Adjusted EBITDA a more representative measure of operational improvement. The company continues to execute on strategic initiatives, including the FDA approval of a yield enhancement process expected to boost future margins, the divestiture of three plasma collection centers for $12.0 million to optimize its supply model, and the advancement of its SG-001 hyperimmune globulin pipeline with a pre-IND submission anticipated in 2026. The Board also authorized a $500 million share repurchase program, with $32.090 million executed in 2025, signaling confidence in future value. These comprehensive results and strategic updates provide a clear, positive outlook for investors.